Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04370782 · ClinicalTrials.gov registry record · Phase 4
Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting
A Phase 4 study, sponsored by St. Francis Hospital, New York.
- Completed
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
NCT04370782: Completed Phase 4 study, sponsored by St. Francis Hospital, New York.
NCT04370782 is a Phase 4 study that has completed, run by St. Francis Hospital, New York. The registered enrollment target is 18 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04370782, a Phase 4 study, has completed, sponsored by St. Francis Hospital, New York.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a randomized, open-label trial to assess the safety and efficacy of hydroxychloroquine, and zinc in combination with either azithromycin or doxycycline in a higher risk COVID-19 positive outpatient population.
Primary Outcome
Patients will be assessed on day 5 for when COVID-19 symptoms completely resolve compared to baseline (day 1 of trial)
Interventions
- DRUG Azithromycin
- DRUG Doxycycline
- DRUG Hydroxychloroquine
- DRUG Zinc Sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-04-28 |
| Est. Completion | 2020-09-30 |
| Phase | Phase 4 |
What the finished NCT04370782 record still lists
NCT04370782 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 4 interventions - of which Azithromycin is the first listed.
NCT04370782 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04370782 about?
NCT04370782 is a clinical study titled "Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting". This is a randomized, open-label trial to assess the safety and efficacy of hydroxychloroquine, and zinc in combination with either azithromycin or doxycycline in a higher risk COVID-19 positive outpatient population.
What is the current status of trial NCT04370782?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2020-04-28. Estimated completion is 2020-09-30.
What interventions are being tested in trial NCT04370782?
The interventions under investigation include: Azithromycin (DRUG), Doxycycline (DRUG), Hydroxychloroquine (DRUG), Zinc Sulfate (DRUG).
Who is sponsoring clinical trial NCT04370782?
This trial is sponsored by St. Francis Hospital, New York, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04370782's enrollment target sits among peer trials
18 1842nd of 2000 higher than 147 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI